Lecanemab Filing Complicates Biogen's Hunt For New CEO
Pivotal Trial Result Expected In Q3
Executive Summary
Lecanemab is now filed for accelerated approval with the US FDA, but the wait for a Phase III readout could impact the hunt for Biogen’s next CEO.